Now is the perfect time to buy these 3 healthcare stocks!

These three companies have stunning long-term return potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The outlook for the global economy may be bright, but it’s also uncertain. US interest rate rises, the US election and Brexit all loom on the horizon and could cause investors to move towards a more risk-off mentality. That’s a big reason why healthcare has huge appeal at the moment due to its defensive characteristics.

GlaxoSmithKline

For example, GlaxoSmithKline (LSE: GSK) is an exceptionally well-diversified business. It has three world-class divisions: consumer goods, vaccines and pharmaceuticals and this reduces its risk profile. It means that disappointment in one segment can be offset by strong performance elsewhere and with GlaxoSmithKline having a pipeline of around 40 potential treatments, the company offers excellent growth prospects, too.

In fact, it’s forecast to increase its earnings by 7% next year. This will boost its dividend coverage ratio, which will make its shareholder payouts more sustainable over the long run. On this topic, the company yields 4.7% from a dividend covered 1.3 times by profit. Although dividends aren’t due to rise over the next couple of years, beyond that GlaxoSmithKline’s growth potential indicates that shareholders will be rewarded through higher dividends in the long run.

Shire

While Glaxo offers top-notch income potential, Shire’s (LSE: SHP) yield of 0.4% holds little appeal for income seeking investors. However, this could change over the long run. A key reason for that is Shire’s combination with Baxalta, which is set to provide synergies and a more robust pipeline.

The deal is forecast to boost Shire’s bottom line, with growth of 18% forecast for next year. This puts Shire on a price-to-earnings growth (PEG) ratio of 0.7, which indicates that it offers strong growth at a very reasonable price.

This growth potential is set to catalyse Shire’s dividend payouts. They’re forecast to rise by 22% next year and while this doesn’t suddenly make Shire a top-notch income play, the fact that its dividends are covered 14.8 times by profit indicates that its shareholder payouts could be at the start of a period of significant growth.

Advanced Medical Solutions

As well as those two, Advanced Medical Solutions (LSE: AMS) is a worthy purchase right now. Its business model is very sound and consistent, with its focus on wound care providing a reliable financial outlook. In fact, in the last five years Advanced Medical Solutions has increased its earnings in every year, recording an annualised growth rate of 13% during the period.

Looking ahead, it’s expected to continue this growth with 7% forecast in each of the next two years. As with Shire, its yield of 0.4% lacks appeal for income-seeking investors, but with dividends being covered 8.2 times by profit, there’s scope for a rapid rise in shareholder payouts. As such, a 13% rise in dividends is due next year.

However, for investors who are only able to buy one of the three stocks discussed here, GlaxoSmithKline’s mix of growth and income marks it out as the most appealing buy for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Advanced Medical Solutions and GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Advanced Medical Solutions. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »